| dc.description.abstract | Dengue Fever (DF) Virus-based Vaccine development showed a relatively slow progress
because it should induce protection against the 4 serotypes of Dengue Viruses and there is a
very limited adequate animal model for dengue virus infection. In the last decade, new
approach in vaccine development for arthropode-borne diseases is using salivary vector
components. This approach based on hyphotesis that arthropode vectors saliva contains
vasomodulator and imunomodulator proteins that could enhance pathogen infection.
Therefore, it should be possible to control pathogen transmission by vaccinating the host
against the molecule(s) in saliva that potentiate the infection, thereby blocking the enhancing
effects of saliva and thus preventing the pathogen from establishing infection in the host
(Transmission Blocking Vaccine, TBV). However, specific component as a potential target
for TBV in Aedes aegypti, as major vector for DF has not yet been identified so far. This
paper wanted to elaborate the immunogenic components from Salivary Gland (SG) of Aedes
aegypti as potential immunomodulatory protein. We have characterized 2 immunogenic
proteins that are only recognized by healthy people living in endemic area and not by people
from non-endemic area. They have molecular weight of 31 & 56 kD. Further molecular
characterization by Mass-Spectrophotometry of those proteins showed that 31 kDa and dan 56
kDa have high similarity with D7-Protein Family (Odorant Binding Protein) & Apyrase,
respectively. These proteins have very important role in vector blood feeding process. This
also supported by the strong immunogenicity of 31 kDa against human sera in healthy people
as well as Dengue patients. The apyrase activity of 56 kD protein has also been proven in this
research. | en_US |
